Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multicenter Phase Ib/II Study to Evaluate the Safety, Efficacy and Pharmacokinetic Characteristics of ANS014004 in Combination With EGFR-TKI in Patients With EGFR Mutation-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT07285148 is registered in ClinicalTrials.gov with Beijing Pearl Biotechnology Limited Liability Company as lead sponsor.

NCT NCT07285148
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07285148 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multicenter Phase Ib/II Study to Evaluate the Safety, Efficacy and Pharmacokinetic Characteristics of ANS014004 in Combination With EGFR-TKI in Patients With EGFR Mutation-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Lead sponsor
Beijing Pearl Biotechnology Limited Liability Company
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
June 30, 2026
Completion date
December 31, 2029
Enrollment
253 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

egfr mutation, met alteration, metastatic lung cancer, non-small cell lung cancer